CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade PROCEPT BioRobotics Corporation - PRCT CFD

39.28
1.63%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.12
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 39.93
Open* 38.59
1-Year Change* -12.4%
Day's Range* 38.59 - 39.86
52 wk Range 24.83-47.75
Average Volume (10 days) 379.24K
Average Volume (3 months) 9.45M
Market Cap 1.70B
P/E Ratio -100.00K
Shares Outstanding 50.50M
Revenue 116.39M
EPS -2.33
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 8, 2023 39.28 0.81 2.11% 38.47 39.98 38.47
Dec 7, 2023 39.93 1.84 4.83% 38.09 39.94 37.63
Dec 6, 2023 38.56 -0.40 -1.03% 38.96 39.96 38.10
Dec 5, 2023 38.94 2.48 6.80% 36.46 38.98 35.89
Dec 4, 2023 37.96 1.74 4.80% 36.22 38.27 36.22
Dec 1, 2023 37.34 0.67 1.83% 36.67 37.73 36.11
Nov 30, 2023 37.02 1.52 4.28% 35.50 38.59 35.50
Nov 29, 2023 36.96 3.21 9.51% 33.75 36.97 33.41
Nov 28, 2023 33.73 -0.29 -0.85% 34.02 34.29 33.41
Nov 27, 2023 34.59 -0.32 -0.92% 34.91 35.29 34.24
Nov 24, 2023 35.18 1.05 3.08% 34.13 35.55 34.13
Nov 22, 2023 34.64 0.67 1.97% 33.97 34.67 33.65
Nov 21, 2023 33.65 1.17 3.60% 32.48 34.15 31.59
Nov 20, 2023 32.95 -0.13 -0.39% 33.08 33.52 32.68
Nov 17, 2023 32.99 -0.19 -0.57% 33.18 33.61 32.48
Nov 16, 2023 33.41 0.68 2.08% 32.73 33.46 32.00
Nov 15, 2023 32.83 -0.54 -1.62% 33.37 34.26 32.83
Nov 14, 2023 33.33 0.63 1.93% 32.70 33.59 32.65
Nov 13, 2023 32.04 2.07 6.91% 29.97 32.65 29.96
Nov 10, 2023 30.96 -0.31 -0.99% 31.27 31.41 29.66

PROCEPT BioRobotics Corporation Events

Time (UTC) Country Event
Monday, February 26, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 PROCEPT BioRobotics Corp Earnings Release
Q4 2023 PROCEPT BioRobotics Corp Earnings Release

Forecast

-

Previous

-
Thursday, April 25, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 PROCEPT BioRobotics Corp Earnings Release
Q1 2024 PROCEPT BioRobotics Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 75.014 34.473 7.717 6.169
Revenue 75.014 34.473 7.717 6.169
Cost of Revenue, Total 37.929 18.608 8.972 8.054
Gross Profit 37.085 15.865 -1.255 -1.885
Total Operating Expense 158.996 88.637 55.519 49.719
Selling/General/Admin. Expenses, Total 88.828 51.036 30.272 28.518
Research & Development 28.981 18.993 16.275 13.147
Operating Income -83.982 -54.164 -47.802 -43.55
Interest Income (Expense), Net Non-Operating -3.172 -5.753 -5.402 0.379
Other, Net 0 0.064 0.185 1.196
Net Income Before Taxes -87.154 -59.853 -53.019 -41.975
Net Income After Taxes -87.154 -59.853 -53.019 -41.975
Net Income Before Extra. Items -87.154 -59.853 -53.019 -41.975
Net Income -87.154 -59.853 -53.019 -41.975
Income Available to Common Excl. Extra. Items -87.154 -59.853 -53.019 -41.975
Income Available to Common Incl. Extra. Items -87.154 -59.853 -53.019 -41.975
Diluted Net Income -87.154 -59.853 -53.019 -41.975
Diluted Weighted Average Shares 44.4 43.676 42.2695 42.2695
Diluted EPS Excluding Extraordinary Items -1.96293 -1.37039 -1.25431 -0.99303
Diluted Normalized EPS -1.88955 -1.37039 -1.25431 -0.99303
Unusual Expense (Income) 3.258
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 33.104 24.404 23.777 20.349 16.691
Revenue 33.104 24.404 23.777 20.349 16.691
Cost of Revenue, Total 14.675 11.913 13.101 10.118 8.205
Gross Profit 18.429 12.491 10.676 10.231 8.486
Total Operating Expense 58.729 52.781 52.075 42.454 34.566
Selling/General/Admin. Expenses, Total 32.441 30.131 26.034 24.754 19.655
Research & Development 11.613 10.737 9.682 7.582 6.706
Operating Income -25.625 -28.377 -28.298 -22.105 -17.875
Interest Income (Expense), Net Non-Operating 0.34 -0.107 0.126 -0.508 -1.309
Other, Net 0
Net Income Before Taxes -25.285 -28.484 -28.172 -22.613 -19.184
Net Income After Taxes -25.285 -28.484 -28.172 -22.613 -19.184
Net Income Before Extra. Items -25.285 -28.484 -28.172 -22.613 -19.184
Net Income -25.285 -28.484 -28.172 -22.613 -19.184
Income Available to Common Excl. Extra. Items -25.285 -28.484 -28.172 -22.613 -19.184
Income Available to Common Incl. Extra. Items -25.285 -28.484 -28.172 -22.613 -19.184
Diluted Net Income -25.285 -28.484 -28.172 -22.613 -19.184
Diluted Weighted Average Shares 45.16 45.066 44.772 44.64 44.324
Diluted EPS Excluding Extraordinary Items -0.5599 -0.63205 -0.62923 -0.50656 -0.43281
Diluted Normalized EPS -0.5599 -0.63205 -0.55646 -0.50656 -0.43281
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Unusual Expense (Income) 3.258
  • Annual
  • Quarterly
2022 2021 2020 2019
Total Current Assets 272.626 326.173 110.256 50.736
Cash and Short Term Investments 221.859 304.32 100.13 42.021
Cash & Equivalents 212.989 290.699 100.13 42.021
Total Receivables, Net 15.272 4.464 1.549 1.099
Accounts Receivable - Trade, Net 15.272 4.464 1.549 1.099
Total Inventory 28.543 13.977 7.477 6.686
Prepaid Expenses 6.175 2.586 0.369 0.312
Other Current Assets, Total 0.777 0.826 0.731 0.618
Total Assets 309.329 337.024 125.971 61.995
Property/Plant/Equipment, Total - Net 32.137 8.324 12.915 8.273
Property/Plant/Equipment, Total - Gross 41.141 15.018 17.703 10.515
Accumulated Depreciation, Total -9.004 -6.694 -4.788 -2.242
Intangibles, Net 1.477 1.75 2.023 2.295
Other Long Term Assets, Total 3.089 0.777 0.777 0.691
Total Current Liabilities 35.29 16.242 14.526 6.79
Accounts Payable 9.391 2.029 1.24 1.444
Accrued Expenses 20.682 11.205 7.824 3.132
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 4.551 0
Other Current Liabilities, Total 5.217 3.008 0.911 2.214
Total Liabilities 112.257 69.933 65.011 32.764
Total Long Term Debt 51.213 50.004 44.407 23.224
Long Term Debt 51.213 50.004 44.407 23.224
Other Liabilities, Total 25.754 3.687 6.078 2.75
Total Equity 197.072 267.091 60.96 29.231
Redeemable Preferred Stock 0 0 243.854 173.068
Common Stock 0.00045 0.00044 0.00042 0.00042
Additional Paid-In Capital 545.753 528.666 18.788 4.808
Retained Earnings (Accumulated Deficit) -348.675 -261.521 -201.668 -148.649
Unrealized Gain (Loss) -0.006 -0.054 -0.014 0.004
Other Equity, Total -0.00045 -0.00044 -0.00042 -0.00042
Total Liabilities & Shareholders’ Equity 309.329 337.024 125.971 61.995
Total Common Shares Outstanding 44.828 43.676 42.2695 42.2695
Cash 8.87 13.621
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 368.668 230.016 245.58 272.626 288.932
Cash and Short Term Investments 287.087 149.691 180.972 221.859 249.217
Cash & Equivalents 277.784 145.756 178.333 212.989 237.14
Total Receivables, Net 34.622 33.173 20.642 15.272 12.838
Accounts Receivable - Trade, Net 34.622 33.173 20.642 15.272 12.838
Total Inventory 42.201 42.636 38.926 28.543 22.358
Prepaid Expenses 3.981 3.739 4.263 6.175 4.519
Other Current Assets, Total 0.777 0.777 0.777 0.777
Total Assets 421.125 272.446 284.458 309.329 324.037
Property/Plant/Equipment, Total - Net 47.731 37.92 34.38 32.137 29.544
Property/Plant/Equipment, Total - Gross 58.938 48.139 44.095 41.141
Accumulated Depreciation, Total -11.207 -10.219 -9.715 -9.004
Intangibles, Net 1.273 1.341 1.409 1.477 1.545
Other Long Term Assets, Total 3.453 3.169 3.089 3.089 4.016
Total Current Liabilities 41.356 35.945 32.504 35.29 27.359
Accounts Payable 13.597 10.036 10.341 9.391 6.331
Accrued Expenses 14.967 12.303 10.406 20.682 12.757
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 12.792 13.606 11.757 5.217 8.271
Total Liabilities 121.769 116.544 111.332 112.257 103.275
Total Long Term Debt 51.307 51.275 51.241 51.213 50.692
Long Term Debt 51.307 51.275 51.241 51.213 50.692
Other Liabilities, Total 29.106 29.324 27.587 25.754 25.224
Total Equity 299.356 155.902 173.126 197.072 220.762
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.0005 0.00045 0.00045 0.00045 0.00045
Additional Paid-In Capital 726.428 558.352 550.27 545.753 541.048
Retained Earnings (Accumulated Deficit) -427.066 -402.444 -377.159 -348.675 -320.503
Unrealized Gain (Loss) -0.006 -0.006 0.015 -0.006 0.217
Other Equity, Total -0.0005 -0.00045 -0.00045 -0.00045 -0.00045
Total Liabilities & Shareholders’ Equity 421.125 272.446 284.458 309.329 324.037
Total Common Shares Outstanding 50.473 45.271 45.009 44.828 44.714
Cash 9.303 3.935 2.639 8.87 12.077
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -87.154 -59.853 -53.019 -41.975
Cash From Operating Activities -80.382 -57.334 -48.343 -43.818
Cash From Operating Activities 2.841 3.324 2.86 1.494
Non-Cash Items 15.418 3.902 2.299 0.195
Cash Interest Paid 4.291 4.75 3.969 0.397
Changes in Working Capital -11.487 -4.707 -0.483 -3.532
Cash From Investing Activities -2.653 -0.592 -0.233 43.153
Capital Expenditures -2.653 -0.592 -0.233 -7.611
Other Investing Cash Flow Items, Total 0 50.764
Cash From Financing Activities 3.612 262.116 106.771 26.527
Issuance (Retirement) of Stock, Net 6.417 262.116 82.086 1.994
Issuance (Retirement) of Debt, Net 1.195 0 24.685 24.533
Net Change in Cash -79.423 204.19 58.195 25.862
Financing Cash Flow Items -4
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -28.484 -87.154 -58.982 -36.369 -17.185
Cash From Operating Activities -35.928 -80.382 -55.208 -35.357 -18.231
Cash From Operating Activities 0.793 2.841 2.178 1.475 0.758
Non-Cash Items 4.473 15.418 8.297 4.109 1.492
Cash Interest Paid 1.121 4.291 3.573 2.369 1.171
Changes in Working Capital -12.71 -11.487 -6.701 -4.572 -3.296
Cash From Investing Activities -5.339 -2.653 -1.787 -0.273 -0.055
Capital Expenditures -5.339 -2.653 -1.787 -0.273 -0.055
Other Investing Cash Flow Items, Total
Cash From Financing Activities 0.38 3.612 4.93 4.153 1.291
Issuance (Retirement) of Stock, Net 0.38 6.417 4.93 4.153 1.291
Issuance (Retirement) of Debt, Net 1.195 0
Net Change in Cash -40.887 -79.423 -52.065 -31.477 -16.995
Financing Cash Flow Items -4
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 13.0725 6582908 -46777 2023-06-30 LOW
CPMG, Inc. Hedge Fund 10.5822 5328867 0 2023-06-30 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.312 3682068 415432 2023-06-30 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 6.0124 3027667 302378 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.567 2299795 549456 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 2.9482 1484622 175529 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.1104 1062730 265072 2023-06-30 LOW
Moll (Frederic H) Individual Investor 1.7619 887233 2711 2023-06-15 LOW
Bellevue Asset Management AG Investment Advisor 1.4725 741517 0 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.4163 713191 119313 2023-06-30 LOW
Loomis, Sayles & Company, L.P. Investment Advisor/Hedge Fund 1.4074 708704 -6688 2023-06-30 LOW
MFS Investment Management Investment Advisor/Hedge Fund 1.3442 676872 134554 2023-06-30 LOW
American Century Investment Management, Inc. Investment Advisor/Hedge Fund 1.1394 573761 573761 2023-06-30 LOW
BNP Paribas Asset Management UK Limited Investment Advisor 1.1101 559025 145495 2023-09-30 MED
Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.0628 535181 0 2023-09-30 LOW
Mirae Asset Global Investments (USA) LLC Investment Advisor 0.9898 498449 -2437 2023-09-30 LOW
Citadel Advisors LLC Hedge Fund 0.9445 475611 -494029 2023-06-30 LOW
Frank, Rimerman Advisors, LLC Investment Advisor 0.9074 456953 0 2023-06-30 LOW
Johnson & Johnson Innovation-JJDC, Inc. Venture Capital 0.7108 357939 0 2023-06-30 LOW
Mcgaughy R Kent Jr Individual Investor 0.6862 345538 117455 2022-12-05 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

PROCEPT BioRobotics Corporation Company profile

About Procept Biorobotics Corp

Procept Biorobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). Its AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. It designs Aquablation therapy to deliver outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Procept Biorobotics Corp revenues increased from $7.7M to $34.5M. Net loss increased 13% to $59.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest expense increase of 10% to $5.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.25 to -$1.38.

Industry: Medical Equipment, Supplies & Distribution (NEC)

900 Island Drive
Suite 210
REDWOOD CITY
CALIFORNIA 94065
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

Gold

2,004.85 Price
-1.180% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 22:00 (UTC)
Spread 0.50

US100

16,080.90 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

0.67 Price
-0.380% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

71.41 Price
+2.320% 1D Chg, %
Long position overnight fee -0.0204%
Short position overnight fee -0.0015%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading